MedTrace Logo

Doctors' Understanding of Survival Statistics

NCT00981019 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 778

Last updated 2011-08-15

Study results available
· View outcomes & findings →

Summary

The probably most commonly used measure for expressing the pay-offs of early detection and treatment are survival rates. Yet, over time and groups this metric comes with several biases and thus, is not reliable for judging such benefits. Epidemiologists recommend using reduction of disease-specific mortality rates instead, which is unbiased. The purpose of the study is to investigate how primary care physicians understand and use different survival measures for determining the benefit of cancer screening tests.

Conditions

  • Screening

Sponsors & Collaborators

  • Dartmouth-Hitchcock Medical Center

    collaborator OTHER

  • Max Planck Institute for Human Development

    lead OTHER

Principal Investigators

  • Odette Wegwarth, Dr. · Max Planck Institute for Human Development

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00981019 on ClinicalTrials.gov